How does an RNA vaccine work? Is it GMO by CRISPR-Cas9 in Vivo?

[izentrop]

It's simple, we don't inject anything with the virus, just the recipe for making a protein, so it can't be mutagenic.

The "spike" protein being the key to entering the virus into the body, it cannot lose it during mutations, which is why we are sure that the vaccine will work, even on mutants.

it's not that simple, the spike protein can mutate and be more efficient to enter the cell, but be less recognized by the antibodies produced by the vaccine.

Yes, for the moment the mutations on the protein remain minor, we know exactly the changes

the majority strain in the West is still D614G. Compared to the Wuhan strain, it has a mutation at position 614 of protein S, an aspartic acid has given way to a glycine. A change which seems minor but which allowed the mutant D614G to replace the original strain. https://www.futura-sciences.com/sante/a ... rus-85822/

the N501Y mutation means that, at the position of the 501st amino acid of protein S, an asparagine (N) has replaced a tyrosine (Y). Likewise, E484K means that glutamic acid (E) has replaced lysine (K) as the 484th amino acid in protein S. https://www.vidal.fr/actualites/26672-c ... -t-on.html

and vaccines remain effective.

For a more significant modification, the messenger RNA vaccines can quickly modify the recipe of manufacture of the amino acids composing the new protein, to be effective again ...

[Janic]

and vaccines remain effective.

ostensibly!

[izentrop]

and vaccines remain effective.

ostensibly!

Usual "truism" which really advances the debate
Vidal's article is very long

Vaccine producing laboratories (for example Novavax, Pfizer or Moderna) have announced that they are already producing vaccines modified from S proteins of the B.1.351 and P.1 lines. The scenario of periodic boosts with vaccines adapted to the predominant lines of the moment seems to be taking shape.

In conclusion, many uncertainties remain regarding the real impact of these emerging lines of SARS-CoV-2, both in terms of the evolution of the pandemic and the impact on the efficacy of current vaccines. While it seems clear that the B.1.351 and P.1 lines can increase the risk of reinfection and reduce the efficacy of certain vaccines, it is too early to draw any conclusions about their effects on the evolution of the disease. pandemic.

2 mRNA vaccines and a newcomer:

Of what consistsNVX-CoV2373 vaccine ?
NVX-CoV2373 vaccine consists of SARS-CoV-2 Spike (S) proteins, in their entirety, including the transmembrane region. Produced in insect cells (from larvae of the American corn moth, Spodoptera frugiperda) infected with a recombinant baculovirus, these proteins are slightly modified so that the polybasic cleavage site (the "hinge" between the two subunits of S) is stable, the S protein then being immobilized in its “pre-fusion” configuration with the target cell.
The transmembrane part of these proteins is inserted into lipid nanoparticles. One thus obtains “rosettes” each carrying a few copies of S, presented to the immune cells as is the case with a particle of SARS-CoV-2.
To this construction is added an original adjuvant, developed by Novavax, Matrix-M, a derivative of saponins extracted from Panama wood (Quillaja saponaria molina). This adjuvant has been tested in other Novavax vaccine projects in more than 4 people aged 300 months to 5 years, including pregnant women.
This vaccine, presented in liquid form, can be stored at a temperature between 2 and 8 ° C.

Highly immunogenic, this vaccine has succeeded, in macaques, in obtaining what no vaccine against COVID-19 had obtained until now: sterilizing immunity, without traces of virus in the respiratory tract after experimental infection. In addition, previous results relating to the effects of its adjuvant gave hope for an immunity capable of adapting to viral variations, an essential property in these times of emerging variants.

The results of these tests are mixed: a good rate of protection against the "historic" variant (95,6%) and the "British" variant (85,6%), but a poorer performance against the "variant". South African ”: 60,1% in HIV / AIDS negative patients; 49,4% in a population comprising 5,6% of HIV + patients. Although a little disappointing, a protection rate of 60% nevertheless remains above the requirements of health regulatory agencies.

In addition, the phase 2b study conducted in South Africa has shown that people with antibodies against the "historical" variant of SARS-CoV-2 have the same risk of reinfection with the "South African" variant. than those who have never developed COVID-19 in the past.

Another Phase 3 trial, larger than the one in the UK, is underway in the US and Mexico. Finally, Novavax announced that it has started to develop a new version of its vaccine including the S proteins of emerging variants.(in particular “South African” and “Brazilian”), which will be the subject of a clinical study starting in the spring. https://www.vidal.fr/actualites/26613-v ... odium.html

[Obamot]

There is nothing to confirm that they are effective, the labs have been careful not to offer a “guarantee of results”.
They did not even make a promise, giving a percentage of effectiveness while having said in a totally contradictory way (something like): the effect of the vaccines on the spread would not have been the criterion!

Yes, for the moment the mutations on the protein remain minor, on knows exactly the changes

Who is “we”

[Christophe]

RNA therapies: blind patient regains sight for a year after single injection

In a trial of a new RNA therapy, a patient with a severe genetic retinal disease regained sight after a single injection.

[GuyGadeboisTheBack]

There is nothing to confirm that they are effective, the labs have been careful not to offer a “guarantee of results”.
They did not even make a promise, giving a percentage of effectiveness while having said in a totally contradictory way (something like): the effect of the vaccines on the spread would not have been the criterion!

Yes, for the moment the mutations on the protein remain minor, on knows exactly the changes

Who is “we”

Well, "we" are Izy and his pals, epidemiologists, virologists and first-rate researchers with whom he drinks pots every night and with whom he cuts off the fat.

[Janic]

with which he cuts .... the fat tip. Name of'a pipe, he got away with it!

[Obamot]

Am sure he doesn't even know the role of a protein (damn he's going to rush to wikipedia now ... like ABC for the placebo!)

[Christophe]

The 1st episode of "Once Upon a Time in Life" aired in 1988:

La_vie.jpeg (325.43 KiB) Viewed 1246 times

[Christophe]

Sanofi no longer wants to be overtaken!

sanofi_arn_translate.png (68.98 KiB) Viewed 839 times